← Back to Search

Platinum-based agent

Aroplatin for Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Aronex Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Amenable to therapy with DACH platinum agents

Women of childbearing potential must have a negative urine or serum pregnancy test

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see how well it works and how long it works for.

Who is the study for?

This trial is for adults with advanced solid tumors like ovarian, colorectal, liver, esophageal, or pancreatic cancer. Participants must be able to receive DACH platinum drugs and have a measurable disease. They should be relatively stable (ECOG score 0-2), not pregnant, and without serious illnesses or brain metastases.Check my eligibility

What is being tested?

The study tests Aroplatin's safety and effectiveness in treating various advanced cancers. It aims to see how patients respond to the treatment and how long their response lasts.See study design

What are the potential side effects?

While specific side effects of Aroplatin are not listed here, similar chemotherapy agents can cause fatigue, nausea, kidney issues, nerve damage (neuropathy), low blood cell counts leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can be treated with DACH platinum-based chemotherapy.

Select...

I am a woman who can have children and have a negative pregnancy test.

Select...

I can take care of myself and am up and about more than half of the day.

Select...

My cancer is in an advanced stage and not just in one place.

Select...

My heart works well enough for daily activities without severe symptoms.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Aronex PharmaceuticalsLead Sponsor

5 Previous Clinical Trials

268 Total Patients Enrolled

Media Library

Aroplatin (Platinum-based agent) Clinical Trial Eligibility Overview. Trial Name: NCT00057395 — Phase 1 & 2

Colorectal Cancer Research Study Groups:

Colorectal Cancer Clinical Trial 2023: Aroplatin Highlights & Side Effects. Trial Name: NCT00057395 — Phase 1 & 2

Aroplatin (Platinum-based agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00057395 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which type of patient does this study require?

"This study is seeking 40 individuals, aged 18 or older, that have been diagnosed with esophageal cancer. In addition to this primary criterion, patients must also: have advanced solid malignancies; be responsive to therapy with DACH platinum agents; have measurable disease (RECIST criteria); an ECOG performance score of 0-2; and finally, be willing to participate in follow up treatments and observation."

Answered by AI

Are people of all ages being included in this research?

"This particular trial is only available to those aged 18 years or younger. Out of the 6470 trials that are available for people over 65, 427 of them are also open to applicants under the age of 18."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

2024. "A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00057395.

All > Esophagus Cancer > Hepatocellular Carcinoma